NO20083216L - Myke proteaseinhibitorer og pro-myke former derav - Google Patents
Myke proteaseinhibitorer og pro-myke former deravInfo
- Publication number
- NO20083216L NO20083216L NO20083216A NO20083216A NO20083216L NO 20083216 L NO20083216 L NO 20083216L NO 20083216 A NO20083216 A NO 20083216A NO 20083216 A NO20083216 A NO 20083216A NO 20083216 L NO20083216 L NO 20083216L
- Authority
- NO
- Norway
- Prior art keywords
- soft
- pro
- protease inhibitors
- compounds
- forms
- Prior art date
Links
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 abstract 3
- 239000004365 Protease Substances 0.000 abstract 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 235000019419 proteases Nutrition 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 231100001274 therapeutic index Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75201705P | 2005-12-19 | 2005-12-19 | |
PCT/US2006/047853 WO2007100374A2 (en) | 2005-12-19 | 2006-12-15 | Soft protease inhibitors and pro-soft forms thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083216L true NO20083216L (no) | 2008-09-18 |
Family
ID=38459469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083216A NO20083216L (no) | 2005-12-19 | 2008-07-18 | Myke proteaseinhibitorer og pro-myke former derav |
Country Status (11)
Country | Link |
---|---|
US (5) | US8268880B2 (pt) |
EP (1) | EP1973548A4 (pt) |
JP (1) | JP5270369B2 (pt) |
KR (2) | KR20080077024A (pt) |
CN (1) | CN101379069A (pt) |
AU (1) | AU2006339348B2 (pt) |
BR (1) | BRPI0620027A2 (pt) |
CA (1) | CA2633803A1 (pt) |
IL (1) | IL192134A (pt) |
NO (1) | NO20083216L (pt) |
WO (1) | WO2007100374A2 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0620027A2 (pt) * | 2005-12-19 | 2011-10-25 | Tufts College | inibidores da protease soft e formas pró-soft |
EP2139337A4 (en) * | 2007-03-20 | 2012-09-19 | Tufts College | Inhibitors of Fibroblast Activating Protein and Method of Use |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7838673B2 (en) | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
WO2009051581A1 (en) * | 2007-10-16 | 2009-04-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
CA2706115A1 (en) * | 2007-12-10 | 2009-06-18 | F. Hoffmann-La Roche Ag | Seprase as a marker for cancer |
FR2942409B1 (fr) * | 2009-02-20 | 2013-07-26 | Natacha Voillot | Composition pharmaceutique pour la prevention des avortements a repetition. |
EP2400976B1 (en) * | 2009-02-27 | 2016-12-14 | Trustees Of Tufts College | Soft protease inhibitors, and pro-soft forms thereof |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
DK2753334T3 (da) * | 2011-08-30 | 2022-11-07 | Tufts College | Fap-aktiverede proteasomhæmmere til behandling af solide tumorer |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN106075450A (zh) * | 2011-11-22 | 2016-11-09 | 塔夫茨大学信托人 | 用于树突状细胞癌症疫苗的小分子增强剂 |
US20150202218A1 (en) * | 2012-08-02 | 2015-07-23 | Trustees Of Tufts College | Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections |
WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
CN109906082A (zh) | 2016-09-07 | 2019-06-18 | 塔夫茨大学信托人 | 使用免疫dash抑制剂和pge2拮抗剂的组合治疗 |
US11357829B2 (en) | 2017-02-03 | 2022-06-14 | Vanderbilt University | Systems, compositions and methods for treating diabetes |
US11559537B2 (en) | 2017-04-07 | 2023-01-24 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists |
CN108929340B (zh) * | 2017-05-22 | 2019-12-13 | 北京大学 | 脯氨酸硼酸类化合物及其制备方法和用途 |
US20200319197A1 (en) * | 2017-10-30 | 2020-10-08 | Carmentix Pte. Ltd. | Biomarkers of Preterm Birth |
WO2020006367A1 (en) * | 2018-06-29 | 2020-01-02 | Tufts Medical Center, Inc. | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions |
WO2020047185A1 (en) * | 2018-08-31 | 2020-03-05 | Texas Tech University System | Enhancers of neurolysin activity |
JP7322649B2 (ja) | 2019-10-09 | 2023-08-08 | 株式会社Soken | 安全距離決定装置および安全距離決定方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03220179A (ja) * | 1990-01-23 | 1991-09-27 | Chisso Corp | 新規な環状ジペプチド誘導体及びその製造法 |
US6825169B1 (en) * | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
MX9206628A (es) * | 1991-11-22 | 1993-05-01 | Boehringer Ingelheim Pharma | Ester de prolinaboronato y metodo para su preparacion. |
WO1995011689A1 (en) * | 1993-10-29 | 1995-05-04 | Trustees Of Tufts College | Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells |
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
ES2288807T1 (es) | 1998-02-02 | 2008-02-01 | Trustees Of Tufts College | Uso de inhibidores de dipeptidasa para regular el metabolismo de la glucosa. |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
US7727964B2 (en) * | 2001-11-26 | 2010-06-01 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
AU2002360453C1 (en) * | 2001-11-26 | 2009-06-18 | The Brigham And Women's Hospital, Inc. | Methods for treating autoimmune disorders, and reagents related thereto |
US7638638B2 (en) * | 2003-05-14 | 2009-12-29 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
CA2558106A1 (en) * | 2004-02-23 | 2005-09-09 | Trustees Of Tufts College | Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism |
BRPI0620027A2 (pt) * | 2005-12-19 | 2011-10-25 | Tufts College | inibidores da protease soft e formas pró-soft |
-
2006
- 2006-12-15 BR BRPI0620027-3A patent/BRPI0620027A2/pt not_active IP Right Cessation
- 2006-12-15 US US12/096,876 patent/US8268880B2/en not_active Expired - Fee Related
- 2006-12-15 WO PCT/US2006/047853 patent/WO2007100374A2/en active Application Filing
- 2006-12-15 KR KR1020087017430A patent/KR20080077024A/ko not_active Application Discontinuation
- 2006-12-15 AU AU2006339348A patent/AU2006339348B2/en not_active Ceased
- 2006-12-15 EP EP06849964A patent/EP1973548A4/en not_active Withdrawn
- 2006-12-15 CA CA002633803A patent/CA2633803A1/en not_active Abandoned
- 2006-12-15 CN CNA2006800529362A patent/CN101379069A/zh active Pending
- 2006-12-15 KR KR1020147024336A patent/KR20150003157A/ko not_active Application Discontinuation
- 2006-12-15 JP JP2008547342A patent/JP5270369B2/ja not_active Expired - Fee Related
-
2008
- 2008-06-12 IL IL192134A patent/IL192134A/en not_active IP Right Cessation
- 2008-07-18 NO NO20083216A patent/NO20083216L/no not_active Application Discontinuation
-
2012
- 2012-09-14 US US13/617,790 patent/US8563533B2/en not_active Expired - Fee Related
-
2013
- 2013-09-30 US US14/041,201 patent/US8933056B2/en not_active Expired - Fee Related
-
2014
- 2014-12-16 US US14/572,015 patent/US9192646B2/en not_active Expired - Fee Related
-
2015
- 2015-11-04 US US14/932,560 patent/US20160250237A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006339348A1 (en) | 2007-09-07 |
CN101379069A (zh) | 2009-03-04 |
JP2009521441A (ja) | 2009-06-04 |
WO2007100374A2 (en) | 2007-09-07 |
US8563533B2 (en) | 2013-10-22 |
JP5270369B2 (ja) | 2013-08-21 |
WO2007100374A9 (en) | 2007-12-06 |
AU2006339348B2 (en) | 2013-01-17 |
KR20150003157A (ko) | 2015-01-08 |
EP1973548A4 (en) | 2010-02-24 |
US20130150292A1 (en) | 2013-06-13 |
WO2007100374A3 (en) | 2008-11-13 |
US20150157684A1 (en) | 2015-06-11 |
EP1973548A2 (en) | 2008-10-01 |
CA2633803A1 (en) | 2007-09-07 |
KR20080077024A (ko) | 2008-08-20 |
US20090124559A1 (en) | 2009-05-14 |
US20160250237A1 (en) | 2016-09-01 |
IL192134A (en) | 2013-04-30 |
US20140128344A1 (en) | 2014-05-08 |
US8933056B2 (en) | 2015-01-13 |
US9192646B2 (en) | 2015-11-24 |
BRPI0620027A2 (pt) | 2011-10-25 |
IL192134A0 (en) | 2009-08-03 |
US8268880B2 (en) | 2012-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083216L (no) | Myke proteaseinhibitorer og pro-myke former derav | |
NO20064307L (no) | Inhibitorer av dipeptidylpeptidase IV for regulering av glukose metabolisme | |
IS7817A (is) | Fenýlalanín afleiður sem dípeptidýl peptíðasa hindrar til að meðhöndla eða fyrirbyggja sykursýki. | |
GEP20135791B (en) | Use of dipeptidyl peptidase inhibitors | |
GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
NO20052380L (no) | Beta-amino-heterosykliske dipeptidylpeptidaseinhibitorer for behandling og forhindring av diabetes | |
NO20082048L (no) | Ny formulering | |
NO20064306L (no) | Laktamer som konformasjonelt begrensede peptidomimetiske inhibitorer | |
MX2008012490A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
EP1888066A4 (en) | AMINOCYCLOHEXANES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES | |
EP1796669A4 (en) | AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
WO2003045977A3 (en) | Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes | |
WO2006071762A3 (en) | Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods | |
EP1490335A4 (en) | HETEROCYCLIC BETA-AMINO DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
HN2008000130A (es) | Derivados de isoquinolona sustituidos con piperidinilo en calida de inhibidores de rho-quinasa | |
NO20063483L (no) | Therapeutic combinations | |
TW200722427A (en) | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | |
ATE529531T1 (de) | Gm3-synthase als therapeutisches ziel bei mikrovaskulären komplikationen des diabetes | |
WO2006096769A3 (en) | Use of alpha-glucosidase inhibitors to treat alphavirus infections | |
DK2041181T3 (da) | Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi | |
MY138965A (en) | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
TW200500338A (en) | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
JO2396B1 (en) | Peptidase de peptidyltransferase inhibitors amino builder for the treatment or prevention of diabetes | |
SG165343A1 (en) | Jnk inhibitors for the treatment of endometriosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |